William J. Buffham

William J. Buffham

Auto-generated profile, based on publicly available information

William J. Buffham

Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Open access
AGAngela Glen
Angela Glen
RBRoland W. Bürli
Roland W. Bürli
DLDavid Livermore
David Livermore
WBWilliam Buffham
William Buffham
SMStephanie Merison
Stephanie Merison
NBNicola L. Brice
Nicola L. Brice
Modulators of orexin receptors are being developed for neurological illnesses such as sleep disorders, addictive behaviours and other psychiatric diseases. We herein describe the discovery of CVN766, a potent orexin 1 receptor antagonist that has greater than 1000-fold selectivity for the orexin 1 receptor over the orexin 2 receptor and demonstrates low off target hits in a diversity screen. In agreement with its in vitro ADME data, CVN766 demonstrated moderate in vivo clearance in rodents and displayed good brain permeability and target occupancy. This drug candidate is currently being investigated in clinical trials for schizophrenia and related psychiatric conditions.

27 June 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NPNick Palmer
Nick Palmer
CAChristopher Agnew
Christopher Agnew
CBCaroline Benn
Caroline Benn
WBWilliam J. Buffham
William J. Buffham
JCJoan N. Castro
Joan N. Castro
DTDominic Tisi
Dominic Tisi